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Abstract
Background: To date all efforts to develop a malaria vaccine have failed, reflecting the still
fragmentary knowledge about protective mechanisms against malaria. In order to evaluate if
vaccination changes responses of the anti-malaria effectors spleen and liver to blood stage malaria,
BALB/c mice succumbing to infection with Plasmodium chabaudi were compared to those surviving
after vaccination.
Methods: Mice were vaccinated with host cell plasma membranes isolated from P. chabaudi-
infected erythrocytes. Hepatic and splenic capacity to trap particulate material was determined
after injection of fluorescent polystyrol beads. Hepatic gene expression was measured using real-
time RT-PCR and Northern blotting.
Results: Survival of BALB/c mice was raised from 0% to 80% and peak parasitaemia was decreased
by about 30% by vaccination. Vaccination boosted particle trapping capacity of the liver during crisis
when splenic trapping is minimal due to spleen 'closing'. It also attenuated malaria-induced
inflammation, thus diminishing severe damages and hence liver failure. Vaccination increased
hepatic IFN-γ production but mitigated acute phase response. Vaccination has a complex influence
on infection-induced changes in expression of hepatic nuclear receptors (CAR, FXR, RXR, and
PXR) and of the metabolic enzymes Sult2a and Cyp7a1. Although vaccination decreased CAR
mRNA levels and prevented Cyp7a1 suppression by the CAR ligand 1,2-bis [2-(3,5-
dichloropyridyloxy)]benzene (TCPOBOP) on day 8 p.i., Sult2a-induction by TCPOBOP was
restored.
Conclusion: These data support the view that the liver is an essential effector site for a vaccine
against blood stage malaria: vaccination attenuates malaria-induced inflammation thus improving
hepatic metabolic activity and particle trapping activity of the liver.
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Background
Despite intense efforts to develop a vaccine against
malaria during the last 30 years, a safe and effective vac-
cine candidate is not yet available [1]. One reason for this
failure may be that knowledge about the effector sites and
mechanisms that have to be activated for successful pro-
tection is still rather incomplete. Moreover, natural
immunity to malaria underlies rather complex control. It
is directed against the blood stages of Plasmodium para-
sites, but it is never solid, i.e. it mitigates and can even
completely abolish disease symptoms, but it does not pre-
vent re-infections during malaria seasons [2,3]. In an
experimental malaria model, Plasmodium chabaudi in
rodents, a vaccination model has been previously devel-
oped that resembles natural immunity in so far that it
helps susceptible mice to survive an otherwise lethal
blood stage infection without preventing parasitaemia
[4]. This vaccination model uses host cell plasma mem-
branes of P. chabaudi-parasitized red blood cells (pRBC)
as an immunogen. These erythrocyte membranes contain
several parasite proteins [5,6] the functions of which have
remained unknown to date, including a major immuno-
genic P. chabaudi protein Pc90 against which most of the
antibodies induced by this type of vaccination are directed
[4]. This vaccination model is used here to further study
the effector sites and mechanisms, which have to be acti-
vated to survive blood stage infections.
The spleen is widely considered to be the central effector
site of the host defence against blood stage malaria [7,8],
and it is thought to destroy pRBC by the same mecha-
nisms which normally remove senescent and other aber-
rant erythrocytes from circulation [9]. Basically, pRBC are
eliminated by macrophages in the red pulp areas of the
spleen, specifically in extravascular beds through which
blood is percolated before reaching the collecting veins.
This open circulation and, hence, the direct contact
between pRBC and macrophages, has been described to
become 'closed' during acute P. chabaudi malaria or at
least transiently closed during acute Plasmodium yoelii
17XNL [10,11] and P. chabaudi adami malaria [12]. How-
ever, it is possible that vaccination prevents – at least par-
tially – this 'closing' mechanism, thus enabling the spleen
to destroy pRBC during crisis when parasitaemia is dra-
matically falling.
The liver is another important effector site against blood
stage malaria, though research in this field is largely
neglected to date [13,14]. Indeed, research concentrates
on the role of the liver in the pre-erythrocytic develop-
ment of parasites. However, the liver, although not exhib-
iting any extravascular beds as the spleen, is also able to
phagocytose senescent erythrocytes [15,16] and pRBC
[17,18]. In particular, the intravascular Kupffer cells,
which constitute about 80–90% of all resident macro-
phages of the reticuloendothelial system [19], are compe-
tent for erythrophagocytosis. In P. chabaudi malaria it has
been recently shown that the liver improves its trapping
capacity, especially during crisis of self-healing infections,
i.e. that phase, when the spleen is 'closed' [13,20]. How-
ever, the effect of protective vaccination on liver trapping
capacity has never been investigated to date.
Here, protective vaccination against blood stages of P.
chabaudi is shown to convert non-healer BALB/c mice to
self-healer mice. This vaccination-induced self-healing
coincides with an augmented trapping capacity of the liver
– but not of the spleen – especially during crisis, when
parasitaemia drops from more than 50% to about 1% or
even below. Furthermore, vaccination boosts production
of IFN-γ and strongly attenuates inflammation and pro-
motes recovery of liver metabolism from infection-
induced dysregulation during crisis.
Methods
Mice
BALB/c mice were bred under specific pathogen-free con-
ditions in the central animal facilities at the Max-Planck-
Institute for Immunobiology in Freiburg and at the Uni-
versity of Düsseldorf. Experiments were performed only
with female mice at an age of 10–14 weeks. They were
housed in plastic cages and received standard diet (Wohr-
lin, Bad Salzufeln, Germany) and water ad libitum. In
some experiments, mice received 60 μg of the synthetic
CAR ligand 1,2-bis [2-(3,5-dichloropyridyloxy)] benzene
(TCPOBOP) in 100 μl DMSO by intraperitoneal injection
24 h before they were killed for isolation of RNA. All
experiments were approved by the state authorities and
followed German law on animal protection.
Infections
A non-clonal line of P. chabaudi was used which behaves
very similarly to P. chabaudi chabaudi AS in terms of restric-
tion fragment length polymorphism analysis [14]. Also,
the AS clone and the line used here reveal sequence iden-
tity for dihydrofolate reductase and for a cysteine protease
[21] with only a single nucleotide exchange in the latter
(Krücken and Wunderlich, unpublished data). Blood
stages of P. chabaudi were weekly passaged in NMRI mice
[14,22]. BALB/c mice were challenged with 106  P.
chabaudi-parasitized erythrocytes by intraperitoneal injec-
tion. Parasitaemia was evaluated in Giemsa-stained blood
smears. Total erythrocytes were counted in a Neubauer
chamber.
Vaccination
Mice were vaccinated with a modified procedure that has
been developed previously [4]. As an immunogen, host
cell plasma membranes were used which were isolated in
the form of ghosts from P. chabaudi-pRBC as describedMalaria Journal 2009, 8:54 http://www.malariajournal.com/content/8/1/54
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elsewhere [23]. About 106 ghosts in 100 μl FCA were sub-
cutaneously injected twice, three weeks and one week
before challenging with P. chabaudi pRBC. Controls
received plasma membranes in the form of ghosts from
non-infected erythrocytes in FCA or only FCA.
Flow cytometry
Spleens were processed for flow cytometry in a FACScan
(BD Biosience) as detailed previously [14]. After aseptic
removal, spleens were gently dissociated through a stain-
less steel sieve into RPMI medium (Invitrogen) supple-
mented with 5% foetal calf serum (PAA Laboratories).
After lysis of erythrocytes by NH4Cl, total leukocytes were
counted in a Neubauer chamber. Leukocytes were prein-
cubated with anti-CD16/CD32 (FcIII/II receptor) FC
block (BD Bioscience) for 15 min and then labelled with
one of the following FITC-labelled monoclonal antibod-
ies: anti-mouse CD45R/B220 (clone RA3-6B2), anti
mouse CD4 (H129.19), anti-mouse CD8a (53-6.7), anti-
mouse CD244.2 (2B4), anti-mouse Br1 (RB6-8C5) (all
BD Bioscience), and anti-mouse F4/80 (C1:A3-1) (Immu-
nokontact). FACS analyses were done with a sample size
of 10.000 cells gated on the basis of forward and sideward
scatter [24]. Data were stored and processed using Cell
Quest Pro software (BD Bioscience).
Trapping capacity
Trapping of 3 μm green fluorescent polystyrol beads
(Ducke Scientific corporation, Palo Alto, California) was
measured according to the procedure described recently
[13,20]. Particles were intravenously injected, mice were
killed 5 min later, spleens and parts of livers were
removed, weighed and then incubated in ethanolic KOH,
to which 5 × 105 red fluorescent beads (diameter 2.9 μm)
were added as an internal standard. The samples were
incubated until complete tissue resolution before fluores-
cence of beads was measured in a spectrometer (Perkin
Elmer LS 55, Germany) at excitation/emission wave-
lengths (450/480) and (520/590) for green and red beads,
respectively. For localization of beads [20], cryosections of
spleen and liver were stained with haematoxilin and
eosin. Fluorescence and bright field pictures of the same
field were take separately and superimposed electroni-
cally.
RNA-Isolation
Spleens and liver pieces were aseptically removed, rapidly
frozen, and stored in liquid N2. Total RNA was isolated
using Trizol (Invitrogen).
Northern blot analysis
Total RNA (20 μg) was glyoxylated, separated in agarose
gels, and transferred to positively charged Biodyne7PLUS
nylon membrane (PALL Corporation, Pensacola, FI) as
described previously [25]. Hybridiziation was carried out
with cDNA fragments labelled with [α32P]dCTP using the
DecaLabel™ DNA Labeling Kit (Fermentas) in ExpressHyb
solution (Clontech) at 65°C overnight [26]. Blots were
washed at 65°C twice for 15 min in 2 × SSC, 0.1% SDS
and twice for 30 min in 0.1 × SSC, 0.1% SDS, and sub-
jected to autoradiography at -80°C using Biomax MS film
and screen (Kodak). For densitometric analyses, autoradi-
ographs were scanned and evaluated using QuantiScan
3.0 software (Biosoft, Cambridge, UK).
Quantitative real-time RT-PCR
Contaminating genomic DNA was removed from total
RNA by digestion with DNase using the DNA-free™ kit
(Ambion). Then, cDNA was synthesized using the Quant-
iTect® Reverse Transcription kit (Qiagen) which includes
an additional step to remove contaminating genomic
DNA. Amplifications were performed in a TaqMan7500
(AppliedBiosystems) using QuantiTect™ SYBR®  Green
PCR kit (Qiagen) and gene-specific QuantiTect™ primer
assays (Qiagen) according to the manufacturer's instruc-
tions. Following an initial incubation at 50°C for 2 min,
Taq polymerase was activated by incubation at 95°C for
10 min. During the following 55 cycles made up of 15 s at
95°C, 35 s at 60°C, and 30 s at 72°C, the amount of dou-
ble stranded PCR product was measured as SYBR green
fluorescence at the end of the extension phase. All PCR
reactions yielded only a single product species of the
expected size as revealed by melting point analysis and gel
electrophoresis. Relative quantitative evaluation of ampli-
fication data was done using Taqman7500 system soft-
ware v.1.2.3f2 (AppliedBiosystems) and the 2-ΔΔc
T method
[27]. Expression of the genes of interest was compared to
18S rRNA.
Statistical analyses
Differences between vaccinated and non-vaccinated mice
were analysed using Student's t tests.
Results
Protective vaccination
The vaccination procedure used here converts mice from
a non-healer to a self-healer phenotype, i.e. it prevents
mortality, but it does not prevent parasitaemia [4].
Indeed, female BALB/c mice are highly susceptible to P.
chabaudi malaria. Challenge with 106 P. chabaudi-parasit-
ized erythrocytes resulted in a peak parasitaemia of
approximately 58% on day 7 p. i. (Figure 1). Though the
following crisis was characterized by falling parasitaemia,
all mice succumbed to infection during this period. Vacci-
nation, however, protected BALB/c mice against otherwise
fatal P. chabaudi malaria. Indeed, more than 80% of these
mice survived the infection (Figure 1). Vaccination did
not prevent parasitaemia, but peak parasitaemia was sig-
nificantly decreased to 42%, which dropped during crisis
to about 1% and in individual mice to even below 1% onMalaria Journal 2009, 8:54 http://www.malariajournal.com/content/8/1/54
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day 13 p.i. (Figure 1). Mice vaccinated with erythrocyte
ghosts from non-infected mice were not protected, i.e. all
mice succumbed to infection during crisis. The same was
observed in control mice, which received only FCA.
Remarkably, blood glucose level, anaemia, and percent-
age of reticulocytes in the blood did not significantly dif-
fer between vaccinated and non-vaccinated mice
(Additional file 1).
Particle trapping by liver and spleen
Though vaccination did not directly affect spleen size in
terms of weight, there was an indirect effect on size, which
became evident upon infection. Thus, increase in splenic
weight of vaccinated mice was about twice as much as in
non-vaccinated mice (Figure 2A). In the latter, average
spleen weight rose from about 130 mg on day 0 to about
660 mg on day 8 p.i. Infection of vaccinated mice resulted
in a dramatic increase to more than 1,200 mg per average
spleen on day 8 p.i. (Figure 2B). On day 0 p.i., vaccination
already induced a significantly increased proportion (Fig-
ure 3A) and absolute number (Figure 3B) of phagocytes in
the spleen, i.e. frequency of Gr1+ granulocytes increased
by about 75% and that of F4/80+ macrophages increased
by about 40% (Figure 3). This vaccination-induced
increase in phagocytes was retained during infection.
However, the frequency of different lymphoid cell popu-
lations was not significantly altered by vaccination with
the exception of B220+ B cells showing a significant but
temporary increase in absolute number on day 4 p.i. (Fig-
ure 3B).
In preliminary experiments, particle trapping by spleen
and liver was analysed by fluorescence microscopy after
injection of 3 μm fluorescent beads. Splenic cryosections,
taken on day 0 p.i., clearly show trapping of beads pre-
dominantly in the marginal zone of the spleen that was
lost around peak parasitaemia (Figure 2A) as described
previously for C57BL/6 mice [20]. Hepatic sections reveal
a more or less uniform distribution of trapped beads in
the liver on days 0 and 8 p.i., however, on day 11 p.i.
beads appear to be restricted predominantly to regions
with large distance to the central veins (Figure 2A). The
cryosections were insufficient to resolve whether trapped
beads have been directly phagocytosed by macrophages,
adhere to the surface of phagocytic cells or are passively
trapped in the organs. Incidentally, paraffin sectioning
was not possible since all solvents used for dewaxing the
sections did also dissolve the beads.
Since number of beads varied considerably between slides
a more quantitative method employing dissolution of tis-
sues by ethanolic KOH followed by fluorescence spectros-
copy was used to look for differences in particle trapping
between vaccinated and non-vaccinated mice. Despite the
increase in the frequency of phagocytic cells in the spleen,
vaccination did not significantly affect the specific capac-
ity of the spleen to trap particles – neither before nor dur-
ing infection. After injection of 3 μm fluorescent
polystyrol beads, approximately 2.2 × 105 particles/100
mg spleen were trapped in non-vaccinated mice and
about the same number in vaccinated mice before infec-
tion (Figure 2B). On day 4 p.i., trapping capacity
remained at about the same level as before, but at peak
parasitaemia on day 8 p.i., there was a dramatic reduction
in particle trapping both in vaccinated and non-vacci-
nated mice (Figure 2B).
Obviously, the entry of particles into the spleen was
largely prevented at peak parasitaemia. This so-called
'closing' of the spleen lasted during the major part of crisis
and, only at the end of crisis, a slight 'reopening' began in
vaccinated mice, but the spleen re-gained its initial trap-
ping capacity only on day 36 p.i. – if at all (Figure 2B).
Despite the enormous malaria-induced splenomegaly in
vaccinated mice, total splenic uptake of fluorescent beads
Vaccination-induced protection against P. chabaudi malaria Figure 1
Vaccination-induced protection against P. chabaudi 
malaria. BALB/c mice were vaccinated with ghosts from 
pRBC (+ vacc (pG); n = 18) or were not vaccinated (- vacc 
(untreated); n = 8) or were treated with ghosts from non-
infected erythrocytes in FCA (nG; n = 8), or treated only 
with FCA (FCA; n = 17), before challenging with 106 pRBC. 
All values are means and half standard errors of the mean 
(S.E.M.). **, p < 0.01, *, p < 0.05 vs. peak parasitaemia in vac-
cinated mice. The crisis phase (days 8–13 p.i.) is accentuated 
in grey.
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was not significantly higher during crisis. However,
splenomegaly resulted in rapid recovery of total splenic
trapping capacity after crisis.
Since preliminary tests had shown that there were no sig-
nificant effects of vaccination or P. chabaudi infection on
liver weight, trapping capacity was only determined for
pieces of liver and no total liver trapping capacity was
determined. In contrast to spleen, specific trapping capac-
ity per 100 mg liver was significantly affected by vaccina-
tion, which became evident upon infection during crisis
(Figure 2B). Indeed, vaccination did neither affect the size
of the liver nor modify the capacity of the liver to trap par-
ticles before infection. On day 4 p.i., there was an increase
Splenic and hepatic particle trapping during P. chabaudi malaria Figure 2
Splenic and hepatic particle trapping during P. chabaudi malaria. (A) Localization of 3 μm green fluorescent beads in 
splenic and hepatic cryosections of non-vaccinated BALB/c mice. The scale bar represents 200 μm. (B) Quantification of splenic 
and hepatic trapping. BALB/c mice were vaccinated (+vacc) or not vaccinated (-vacc) and then were challenged with 106 pRBC. 
Parasitaemia, spleen weight, and total number of beads per spleen, and numbers of beads per 100 mg spleen or liver are given 
as means ± S.E.M. The crisis phase (days 8–13 p.i.) is accentuated in grey. ***, p < 0.001 vs. non-vaccinated control on the same 
day p.i. *, p < 0.05 vs. non-vaccinated control on the same day p.i.
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in the trapping capacity of the liver, but on day 8 p.i., there
was a decline to about the initial trapping capacity with
no difference between vaccinated and non-vaccinated
mice (Figure 2B). During crisis, particle trapping further
dropped in non-vaccinated control mice, whereas vacci-
nated mice exhibited a sharp increase in their capacity to
trap particles in the liver and this increase further pro-
gressed reaching a maximum on day 14 p.i., i.e. shortly
after crisis (Figure 2B).
Liver inflammation
In order to detect possible effects of vaccination on
inflammatory and immune responses in the liver, real-
time RT-PCR was used to measure the proinflammatory
cytokines IL-1β, TNF, and IL-6 and the TH1 cytokine IFN-
γ, which is protective against P. chabaudi malaria [28-30].
The mRNA levels of these cytokines followed a biphasic
pattern in non-vaccinated mice during infection, with a
first peak on day 1 p.i. and a second peak on day 8 p.i.
(Figure 4). After vaccination, infection induced a large
increase in expression of IFN-γ especially on days 1 and 8
p.i., whereas vaccination dampened the infection-induced
increases in mRNA levels for the proinflammatory
cytokines IL1-β, TNF, and IL-6 – in particular around peak
parasitaemia. Kupffer cells are a well-known source of
these cytokines in the liver suggesting strong Kupffer cell
activation in non-vaccinated mice during malaria. In
accordance, mRNA levels of iNOS, marker for M1 macro-
phages, also exhibited a biphasic expression pattern in
response to infection, whereas induction of iNOS by P.
chabaudi malaria is largely depressed in vaccinated mice
(Figure 4). Arginase, a marker for alternatively activated
M2 macrophages, followed about the same expression
profile as iNOS although at much lower levels.
In the liver, the above proinflammatory cytokines are
especially known to induce acute phase and other innate
immune responses. Expression profile of two acute phase
proteins and one proinflammatory chemoattractant were,
therefore, compared between vaccinated and non-vacci-
nated mice. Similar to the cytokines, total serum amyloid
Cellular composition of the spleen during P. chabaudi malaria Figure 3
Cellular composition of the spleen during P. chabaudi 
malaria. Vaccinated (black columns) and non-vaccinated 
(gray columns) mice were infected with 106 P. chabaudi pRBC 
and spleen cells were isolated on the days indicated. The fre-
quency (A) and total number (B) of CD4+ and CD8+ T cells, 
F4/80+ macrophages, Gr1+ granulocytes, B220+ B cells, and 
CD244+ NK cells among nucleated spleen cells are given as 
means + half S.E.M. **, p < 0.01 vs. non-vaccinated control on 
the same day p.i. *, p < 0.05 vs. non-vaccinated control on 
the same day p.i.
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Real-time RT-PCR analysis of cytokines, iNOS, andarginase  (ARG) in the liver Figure 4
Real-time RT-PCR analysis of cytokines, iNOS, 
andarginase (ARG) in the liver. Expression was analysed 
in hepatic RNA from vaccinated (circles) and non-vaccinated 
(triangles) mice on the indicated days after challenging with P. 
chabaudi. Signals for genes of interest were normalized to 
18S rRNA signals and relative expression is given as fold 
increase compared to non-vaccinated mice on day 0 p.i. All 
values are mean and half S.E.M. ***, p < 0.001 vs. non-vacci-
nated control on the same day p.i. **, p < 0.01 vs. non-vacci-
nated control on the same day p.i. *, p < 0.05 vs. non-
vaccinated control on the same day p.i.
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A (SAA) followed a biphasic kinetic during infection in
non-vaccinated mice (Figure 5). Vaccination, however,
abolished this biphasic pattern due to decreased expres-
sion, especially on days 8 and 11 p.i. By contrast, C-reac-
tive protein (CRP) and the CXC chemokine ligand
CXCL10 were activated only in the early phase of precrisis,
i.e. on days 1 and 4 p.i., and their induction by infection
was largely prevented by vaccination.
Liver metabolism
IL-1β, TNF and IL-6 are also well known to depress liver
metabolism by interfering with expression of key nuclear
receptors regulating expression of hepatocyte-specific
metabolic enzymes [31-35]. Therefore, mRNA levels of
five members of the nuclear receptor family were exam-
ined by real-time RT-PCR. Infection caused a transiently
increased expression of RXR, FXR, CAR, PXR, and VDR in
non-vaccinated mice, however, expression dramatically
dropped during crisis on day 11 p.i (Figure 6). In contrast,
vaccinated mice initially showed increased mRNA levels
of these receptors before infection (day 0 p.i.), whereas
infection down-regulated their expression on days 1, 4
and 8 p.i. (Figure 6). Surprisingly, however, these recep-
tors were significantly up-regulated again during crisis. By
the end of crisis, there was an almost complete recovery of
RXR, FXR, and CAR to those levels induced by vaccination
before infection, whereas PXR and VDR were significantly
higher expressed (Figure 6).
Northern blot analyses of inflammatory markers in the liver Figure 5
Northern blot analyses of inflammatory markers in 
the liver. Hepatic RNA isolated from P. chabaudi-infected 
vaccinated (+ vacc) or non-vaccinated (-vacc) mice on the 
days indicated was hybridized to probes recognizing all iso-
forms of SAA, CRP, or CXCLl10 before reprobing with an 
18S rRNA-specific probe. Blots are representative of at least 
three independent experiments.
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Real-time RT-PCR analyses of nuclear receptor expression in  the liver Figure 6
Real-time RT-PCR analyses of nuclear receptor 
expression in the liver. Levels of RXR, FXR, CAR, PXR, 
and VDR mRNA were analysed in hepatic RNA of vaccinated 
(circles) and non-vaccinated (triangles) mice on the indicated 
days after P. chabaudi infection. Signals were normalized to 
18S rRNA and relative expression is given as fold increase 
compared to non-vaccinated mice on day 0 p.i. All values are 
mean and half S.E.M. **, p < 0.01 vs. non-vaccinated control 
on the same day p.i. *, p < 0.05 vs. non-vaccinated control on 
the same day p.i.
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Rapid destruction of pRBC is expected to lead to highly
elevated levels of cholesterol-derived toxic bile acids and
haem-derived bilirubin. Since CAR is involved in regula-
tion of both bile acid detoxification [36] and bilirubin
elimination [37], CAR activity during malaria is of partic-
ular interest. Expression of the positive and negative CAR
response genes Sult2a and Cyp7a1 involved in bile acid
detoxification and cholesterol degradation to bile acids,
respectively, were measured by real-time RT-PCR. These
analyses confirmed suppression of Sult2a mRNA levels by
blood stage malaria in BALB/c mice on days 8 and 11 p.i.
(Figure 7A) as previously shown in C57BL/6 and LTβR-/-
mice [13,38]. Vaccination, however, increased Sult2a1
mRNA levels by approximately two- and tenfold on days
0 and 8 p.i., respectively (Figure 7A). Cyp7a1 was severely
down-regulated on days 8 and 11 p.i., whereas vaccina-
tion already induced expression on day 0 p.i. In contrast
to Sult2a1, however, infection strongly intensified
Cyp7a1 down-regulation in vaccinated mice (Figure 7A).
In order to test directly, whether elevated CAR mRNA lev-
els on day 8 p.i. correspond to higher hepatic receptor
activity, mice were challenged with TCPOBOP, a nuclear
receptor ligand known to up-regulate Sult2a [39] and to
down-regulate Cyp7a1 [40] via activation of CAR. Figure
7B clearly shows that treatment with TCPOBOP approxi-
mately doubles Sult2a1 mRNA levels in both vaccinated
and non-vaccinated mice on day 0 p.i. Surprisingly, non-
vaccinated mice on day 8 p.i. did not show any
TCPOBOP-inducibility, but rather displayed TCPOBOP-
induced suppression of Sult2a1 levels. This suppression is
not observable in vaccinated mice, which maintained
inducibility of Sult2a1 by TCPOBOP (Figure 7B),
although they exhibited lower expression of the
TCPOBOP receptor CAR (Figure 6). In order to substanti-
ate these very unusual results, these experiments were not
only confirmed three times with new groups of mice but
also using Northern blotting (Figure 7C) to exclude any
errors due to quantification by PCR.
TCPOBOP-regulation of Cyp7a1 expression revealed an
exactly reciprocal effect. As expected, TCPOBOP sup-
pressed expression of Cyp7a1 in non-vaccinated mice on
days 0 and 8 p.i. and in vaccinated mice on day 0 p.i. (Fig-
ure 7B). In contrast, however, Cyp7a1 mRNA levels were
elevated in vaccinated mice on day 8 p.i. after treatment
with TCPOBOP. Therefore, negative regulation of Cyp7a1
was restricted to non-vaccinated mice with high CAR
mRNA levels, while positive regulation of Sult2a by
TCPOBOP was only observable in vaccinated mice with
low CAR mRNA levels.
Discussion
The vaccination model under investigation here protects
mice against blood stages of P. chabaudi malaria. It does
not prevent parasitaemia, though peak parasitaemia is sig-
nificantly decreased, but rather helps mice to overcome
the disease. Indeed, vaccination converts non-healer to
self-healer mice [4]. Self-healing of P. chabaudi malaria in
turn is known to be associated with acquiring long-lasting
protective immunity against homologous re-challenge
[41]. This capability is normally controlled by genes of the
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Effects of vaccination on malaria-induced suppression 
of SULT2a and CYP7a1. (A) Analysis of hepatic SULT2a1 
and CYP7a1 expression on the indicated days of P. chabaudi 
malaria in vaccinated (triangles) and non-vaccinated (circles) 
mice by real-time RT-PCR. Signals were normalized to 18S 
rRNA signals and relative expression is given as fold increase 
compared to non-vaccinated mice on day 0 p.i. All values are 
means and half S.E.M. (B) Analysis of TCPOBOP effects on 
expression of SULT2a1 and CYP7a1. Vaccinated (+ vacc) or 
non-vaccinated (- vacc) mice were subjected to injection of 
TCPOBOP (grey columns) or vehicle (black columns) before 
analysis of SULT2a1 and CYP7a1 expression on the indicated 
days of P. chabaudi infection using real-time RT-PCR as in (A). 
(C) TCPOBOP effects on expression of SULT2a were con-
firmed by Northern blotting. Blot is a representative of three 
independent experiments. Equal loading of the blot was con-
firmed by rehybridization with a probe specific for 18S 
rRNA.
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H-2 complex and genes of the non-H-2 background [42-
44]. The susceptible BALB/c mice exhibit the malaria-
'resistant' H-2d haplotype, but a malaria-'susceptible' non-
H-2 background [44]. Hence, the vaccination procedure
used here abolishes/overcomes those genetic restrictions
which cause susceptibility and which are controlled by
mouse non-H-2 genes.
Vaccination of BALB/c mice appears to improve the
potential phagocytic capacity of the spleen as indicated by
a significant increase in the percent proportion of both
G1+ granulocytes and F4/80+ macrophages as well as the
concomitant increase in spleen size. Nevertheless, this did
not contribute to an increased trapping capacity since the
spleen became almost 'closed' during peak parasitaemia
and subsequent crisis, when masses of pRBC were
destroyed as evidenced by dramatically falling parasitae-
mias [25]. In contrast to spleen, however, trapping capac-
ity of the liver is augmented after vaccination, especially
during crisis. This augmentation is preceded by a remark-
able increase in the P. chabaudi-induced production of
IFN-γ-mRNA. In accordance, IFN-γ is known to activate
the host defence in other malaria vaccination models too
[45,46]. This supports the view that the liver can function
as an active effector against malarial blood stages, in par-
ticular during crisis, when the spleen is 'closed' [20], i.e.
when the spleen excludes the uptake of pRBC and, thus,
cannot be mechanically involved in the drop of peripheral
parasitaemia observed during crisis.
In the liver, the Kupffer cells are important sites for phago-
cytosis of damaged and senescent erythrocytes [15,16],
and phagocytic activity of Kupffer cells during Plasmodium
berghei malaria has been described to be increased both in
vitro [18] and in perfused livers [17]. The vaccination pro-
cedure used here is shown to modulate hepatic inflamma-
tion as indicated by altered responses of typical
macrophage activation parameters towards to P. chabaudi
malaria. Indeed, P. chabaudi infections induce dramatic
up-regulations of IL-1β, TNF, IL-6, and iNOS in the non-
vaccinated susceptible BALB/c mice. High levels of TNF
have been shown to result in lethal hepatic damage during
blood stage P. chabaudi malaria [47]. Indeed, the increases
in TNF and IL-6 are even about 10-times higher than dur-
ing lethal endotoxic shock [48]. Also, iNOS expression
observed at peak parasitaemia is comparable to that
expression occurring during LPS-induced lethal shock
[49]. These high levels of proinflammatory cytokines and
especially iNOS appear to contribute to severe liver fail-
ure, which entails lower particle trapping during crisis. In
the vaccination model used here, however, there is a sig-
nificant dampening of the infection-induced increase in
IL-1β, TNF, IL-6 and iNOS, especially observable at peak
parasitaemia. This indicates that vaccination does not pre-
vent activation of Kupffer cells and other inflammatory
cells by malaria infection but rather prevents their over-
activation and, hence, severe liver failure. In this context,
it is also noteworthy that high levels of IL-1β and TNF pre-
vent efficient phagocytosis by Kupffer cells, reasonably
due to impaired hepatic microvascular blood flow by pro-
moting leukocyte adhesion to the walls of sinusoids [50].
Thus, vaccination-induced decreases in the expression of
these cytokines, together with the decreased production of
the chemoattractant CXCL10, presumably allow
improved blood circulation in the liver and enhance con-
tact between Kupffer cells and circulating material thus
favouring increased particle trapping in the liver during
crisis.
Conspicuously, mRNA levels of iNOS correlate well with
those of VDR in both non-vaccinated and vaccinated
mice. The mRNAs of iNOS and VDR were strongly up-reg-
ulated by P. chabaudi infection during crisis on days 8 and
11 p.i., and vaccination largely prevented this effect. In
this context, recent findings are noteworthy that VDR sig-
nalling is able to inhibit IFN-γ-induced expression of mac-
rophage activation markers including CXCL10 [51] and
mitigates production of toxic nitric oxide by inducing
arginase expression which lowers the intracellular pool of
the iNOS substrate arginine [52]. In non-vaccinated mice,
induction of arginase is presumably only of minor impor-
tance since iNOS induction is more than 100-fold
stronger than induction of arginase. The up-regulation of
VDR by infection in non-vaccinated mice may thus repre-
sent an insufficient counter-regulatory response to protect
liver tissue from excessive damages due to extreme up-reg-
ulation of iNOS producing high NO levels. In vaccinated
mice, VDR up-regulation appears to be dispensable since
there is only minor induction of iNOS. Although vaccina-
tion strongly down-regulates markers for classically acti-
vated M1 macrophages such as TNF and iNOS, it does not
apparently result in differentiation of macrophages to an
alternatively activated M2 phenotype, since arginase as
marker for alternatively activated macrophages [53] is
even down-regulated by vaccination.
The vaccination-induced attenuation in the inflammatory
response of the Kupffer cells appears to have modulatory
effects on hepatocyte-based reactions involved in the
defence against blood stages of malaria. Indeed, data indi-
cate that vaccination diminishes the infection-induced
acute phase response with respect to the CRP- and SAA3-
proteins. Also, vaccination affects the infection-induced
metabolic response with respect to SULT2A1 and
CYP7A1, respectively. The phase I enzyme CYP7A1 is
involved in cholesterol degradation/bile acid biosynthesis
and the phase II enzyme SULT2A1 in the detoxification of
bile acids, the latter majorly derived from cholesterol
released during destruction of pRBC. At peak parasitae-
mia, the vaccination-induced elevated levels of SULT2AMalaria Journal 2009, 8:54 http://www.malariajournal.com/content/8/1/54
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and decreased levels of CYP7A1 may be, therefore, part of
a protective response, which diminishes liver damages
due to high levels of toxic bile acids.
Liver metabolism including phase I and II detoxifications
are not only regulated by CAR, but also by other nuclear
receptors such as FXR, PXR, and RXR. Here, it is shown
that these nuclear receptors are also responding to both
challenge-infection and vaccination due to cytokines
released by Kupffer cells. Conspicuously, the nuclear
receptors PXR, FXR, RXR, CAR, and VDR are significantly
up-regulated during crisis after vaccination, while non-
vaccinated mice exhibit a down-regulation. However, the
results concerning CAR activation with TCPOBOP show
that mRNA levels of nuclear receptors are not predictive
for hepatic metabolic capacity during blood stage malaria.
The expression of SULT2A and CYP7A1 is known to
respond positively and negatively to CAR activation,
respectively. Direct testing of CAR receptor function by
treating non-vaccinated mice with TCPOBOP revealed
that both P. chabaudi infection and vaccination altered
CAR functionality on day 8 p.i. In non-vaccinated mice,
Sult2a was no longer up- but even down-regulated by
TCPOBOP on day 8 p.i. Vaccination prevented Sult2a
down-regulation and retained its inducibility by
TCPOBOP. Surprisingly, however, vaccination also abol-
ished TCPOBOP-mediated down-regulation of Cyp7a1
on day 8 p.i. and even caused induction of Cyp7a1 by
TCPOBOP. At peak parasitaemia, vaccination apparently
promotes up-regulation of gene expression by CAR and,
concomitantly, interferes with down-regulation. The sim-
plest explanation for this complex response pattern is that
CAR interacts with different cofactors, which determine
whether it acts as a transcriptional activator or repressor.
Characterization of such cofactors in the future will help
to identify pathways leading to liver dysfunction in
malaria and thus provide important information for pro-
phylactic and therapeutic interventions.
Conclusion
The improvement of hepatic trapping and metabolic
capacity in protectively vaccinated mice support the previ-
ous view that the liver has an effector function against
blood stage malaria – at least during acute infection. This
effector function can be strengthened by vaccination due
to dampening the production of the proinflammatory
cytokines IL-1β, TNF, and IL-6 by Kupffer cells. Moreover,
the data presented here suggest that the efficacy of a
human anti-malaria vaccine can be improved by includ-
ing anti-inflammatory components protecting the liver
from overwhelming inflammatory responses.
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